GSK/Innoviva’s triple therapy hits targets in COPD trial
GlaxoSmithKline and Innoviva’s three-drug inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has come out on top in a trial assessing its effectiveness against the dual therapy Symbicort Turbohaler in patients with chronic obstructive pulmonary disorder (COPD).
Read More
